{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:30:09Z","timestamp":1791415809510,"version":"4.3.3"},"reference-count":111,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["patient-research.elsevier.com","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ctrv.2014.04.004","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T10:17:57Z","timestamp":1397816277000},"page":"872-882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":377,"title":["Chemotherapy-induced neuropathy: A comprehensive survey"],"prefix":"10.1016","volume":"40","author":[{"given":"N.C.","family":"Miltenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Boogerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02341156","article-title":"Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement","volume":"9","author":"Boogerd","year":"1990","journal-title":"J Neurooncol"},{"issue":"15","key":"10.1016\/j.ctrv.2014.04.004_b0015","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2014.04.004_b0020","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMcibr1112481","article-title":"Microtubules, axonal transport, and neuropathy","volume":"365","author":"Holzbaur","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/157015906776359568","article-title":"Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives","volume":"4","author":"Scripture","year":"2006","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s004410050019","article-title":"Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro","volume":"299","author":"Theiss","year":"2000","journal-title":"Cell Tissue Res"},{"issue":"203","key":"10.1016\/j.ctrv.2014.04.004_b0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"17","author":"Xiao","year":"2012","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2006.01.037","article-title":"Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction","volume":"122","author":"Flatters","year":"2006","journal-title":"Pain"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2014.04.004_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.2009-S503","article-title":"Pathophysiology and animal models of cancer-related painful peripheral neuropathy","volume":"15","author":"Bennett","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.ctrv.2014.04.004_b0055","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","article-title":"Paclitaxel-induced neuropathy","volume":"6","author":"Postma","year":"1995","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.04.004_b0065","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","article-title":"Paclitaxel (Taxol) induces cumulative mild neurotoxicity","volume":"30A","author":"van Gerven","year":"1994","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0070","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.1999.17.11.3403","article-title":"Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project protocol B-26","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.04.004_b0075","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2009.10.006","article-title":"Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis","volume":"36","author":"Mauri","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/WNL.47.1.115","article-title":"Motor neuropathy due to docetaxel and paclitaxel","volume":"47","author":"Freilich","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1008245400251","article-title":"Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)","volume":"8","author":"Hilkens","year":"1997","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/WNL.50.2.563","article-title":"Lhermitte\u2019s sign following chemotherapy with docetaxel","volume":"50","author":"van den Bent","year":"1998","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies","volume":"35","author":"Chaudhry","year":"1994","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdt173","article-title":"Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment?","volume":"24","author":"Postma","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.04.004_b0110","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0115","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10549-011-1671-3","article-title":"Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)","volume":"130","author":"Sucheston","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ctrv.2014.04.004_b0120","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00415-012-6442-5","article-title":"Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation","volume":"259","author":"Osmani","year":"2012","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.04.004_b0125","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","article-title":"Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3","volume":"112","author":"Rao","year":"2008","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2014.04.004_b0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ctrv.2014.04.004_b0135","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.ejca.2005.04.028","article-title":"Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine","volume":"41","author":"Bianchi","year":"2005","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2014.04.004_b0140","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2014.04.004_b0145","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","article-title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","volume":"14","author":"Lorusso","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1158\/1078-0432.CCR-0772-03","article-title":"Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine","volume":"10","author":"Openshaw","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/\u2212 amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"De Vos","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jpainsymman.2006.03.013","article-title":"Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation","volume":"32","author":"Argyriou","year":"2006","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0165","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00520-010-1018-3","article-title":"The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial","volume":"19","author":"Kottschade","year":"2011","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0170","first-page":"1192","article-title":"Reduction of paclitaxel-induced peripheral neuropathy with glutamine","volume":"7","author":"Vahdat","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clon.2004.11.014","article-title":"Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study","volume":"17","author":"Stubblefield","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2354.2008.00996.x","article-title":"Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel","volume":"18","author":"Loven","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"21","key":"10.1016\/j.ctrv.2014.04.004_b0185","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1021\/bi953037i","article-title":"Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine","volume":"35","author":"Lobert","year":"1996","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01050259","article-title":"Long-term effects of vincristine on the peripheral nervous system","volume":"15","author":"Postma","year":"1993","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10048-012-0313-1","article-title":"Vincristine exacerbates asymptomatic Charcot\u2013Marie\u2013tooth disease with a novel EGR2 mutation","volume":"13","author":"Nakamura","year":"2012","journal-title":"Neurogenetics"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0200","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.WNL.0000154642.45474.28","article-title":"Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening","volume":"64","author":"Verstappen","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0205","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.1996.14.3.935","article-title":"Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine","volume":"14","author":"Weintraub","year":"1996","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2014.04.004_b0210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s002800050551","article-title":"Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel \u2013 a phase II study","volume":"39","author":"Fazeny","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0215","first-page":"323","article-title":"Clinical and electrophysiological studies in vincristine induced neuropathy","volume":"39","author":"Pal","year":"1999","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp.61.4.409","article-title":"Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients","volume":"61","author":"Pace","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0225","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2014.04.004_b0230","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0235","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(25)20981-8","article-title":"Glutamate ameliorates experimental vincristine neuropathy","volume":"279","author":"Boyle","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF03259853","article-title":"Vincristine neurotoxicity. Pathophysiology and management","volume":"1","author":"Legha","year":"1986","journal-title":"Med Toxicol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.04.004_b0245","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2014.04.004_b0250","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roche","year":"2007","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2014.04.004_b0255","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum neurotoxicity pharmacogenetics","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199513040-00003","article-title":"Comparative adverse effect profiles of platinum drugs","volume":"13","author":"McKeage","year":"1995","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0270","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","article-title":"Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity","volume":"10","author":"Gregg","year":"1992","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.04.004_b0275","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1054\/bjoc.2001.2024","article-title":"Nucleolar damage correlates with neurotoxicity induced by different platinum drugs","volume":"85","author":"McKeage","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0280","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00227662","article-title":"Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats","volume":"84","author":"Cavaletti","year":"1992","journal-title":"Acta Neuropathol"},{"issue":"3 Pt 1","key":"10.1016\/j.ctrv.2014.04.004_b0285","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.44.3_Part_1.488","article-title":"The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro","volume":"44","author":"Windebank","year":"1994","journal-title":"Neurology"},{"issue":"Pt 10","key":"10.1016\/j.ctrv.2014.04.004_b0290","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ctrv.2014.04.004_b0295","doi-asserted-by":"crossref","first-page":"201593","DOI":"10.1155\/2011\/201593","article-title":"Oxaliplatin-induced neuropathy in colorectal cancer","volume":"2011","author":"Weickhardt","year":"2011","journal-title":"J Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0305","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0310","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A","article-title":"Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721","volume":"61","author":"Mollman","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.04.004_b0315","first-page":"CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","volume":"2","author":"Albers","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2014.04.004_b0320","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.34.7.934","article-title":"Peripheral sensory neuropathy and cisplatin chemotherapy","volume":"34","author":"Roelofs","year":"1984","journal-title":"Neurology"},{"issue":"Pt 4","key":"10.1016\/j.ctrv.2014.04.004_b0325","first-page":"1076","article-title":"Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies","volume":"130","author":"Krarup-Hansen","year":"2007","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0330","first-page":"18","article-title":"Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies","volume":"70","author":"Beijers","year":"2012","journal-title":"Neth J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Gutierrez-Gutierrez","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0340","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0959-8049(94)00497-S","article-title":"Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration","volume":"31A","author":"Hilkens","year":"1995","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0345","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0277-5379(88)90293-3","article-title":"Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats","volume":"24","author":"Gerritsenvan der Hoop","year":"1988","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0350","first-page":"249","article-title":"Management of oxaliplatin-induced peripheral neuropathy","volume":"1","author":"Saif","year":"2005","journal-title":"Ther Clin Risk Manage"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0355","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4143\/crt.2010.42.4.185","article-title":"Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer","volume":"42","author":"Baek","year":"2010","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ctrv.2014.04.004_b0360","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","article-title":"Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients","volume":"85","author":"Velasco","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.ctrv.2014.04.004_b0365","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","article-title":"Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy","volume":"12","author":"Lecomte","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0370","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1080\/02841860902806609","article-title":"Persistent neuropathy after treatment with cisplatin and oxaliplatin","volume":"48","author":"Brouwers","year":"2009","journal-title":"Acta Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2014.04.004_b0375","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctrv.2014.04.004_b0380","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2014.04.004_b0385","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3959(02)00047-7","article-title":"Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy","volume":"98","author":"Hammack","year":"2002","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0390","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0395","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer \u2013 a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2014.04.004_b0400","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","article-title":"Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"12","author":"Adams","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0405","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejca.2010.10.006","article-title":"The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients","volume":"47","author":"Knijn","year":"2011","journal-title":"Eur J Cancer"},{"issue":"12 Pt 1","key":"10.1016\/j.ctrv.2014.04.004_b0410","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2014.04.004_b0415","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.04.004_b0420","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0425","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clin Neurophysiol"},{"issue":"24","key":"10.1016\/j.ctrv.2014.04.004_b0430","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2014.04.004_b0435","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0440","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2014.04.004_b0445","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0450","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2014.04.004_b0455","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2014.04.004_b0460","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ejca.2006.05.018","article-title":"Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies","volume":"42","author":"Sharma","year":"2006","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2014.04.004_b0465","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ctrv.2014.04.004_b0470","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.04.004_b0475","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2014.04.004_b0480","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1212\/01.WNL.0000130499.91775.2C","article-title":"Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus","volume":"62","author":"Briani","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0485","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ctrv.2014.04.004_b0490","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.04.004_b0495","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0500","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"issue":"9769","key":"10.1016\/j.ctrv.2014.04.004_b0505","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ctrv.2014.04.004_b0510","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0515","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","article-title":"FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"13","author":"Cohen","year":"2008","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ctrv.2014.04.004_b0520","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1899::AID-CNCR9>3.0.CO;2-A","article-title":"Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia","volume":"78","author":"Openshaw","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0525","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJM197407182910305","article-title":"Neurotoxicity of commonly used antineoplastic agents (second of two parts)","volume":"291","author":"Weiss","year":"1974","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2014.04.004_b0530","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.cnd.0000211401.19995.a2","article-title":"Small-fiber neuropathy associated with capecitabine (xeloda)-induced hand-foot syndrome: a case report","volume":"7","author":"Stubblefield","year":"2006","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"10.1016\/j.ctrv.2014.04.004_b0535","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00001813-200409000-00005","article-title":"Peripheral neuropathy associated with capecitabine","volume":"15","author":"Saif","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.ctrv.2014.04.004_b0540","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00001813-200107000-00006","article-title":"Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil","volume":"12","author":"Saif","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"1B","key":"10.1016\/j.ctrv.2014.04.004_b0545","first-page":"647","article-title":"5-FU-induced peripheral neuropathy: a rare complication of a well-known drug","volume":"23","author":"van Laarhoven","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2014.04.004_b0550","series-title":"Neurological complications of cancer","first-page":"241","article-title":"Neurological complications of chemotherapy","author":"Forsyth","year":"1995"},{"issue":"15","key":"10.1016\/j.ctrv.2014.04.004_b0555","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/jco.2008.26.15_suppl.4010","article-title":"Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial","volume":"26","author":"Grothey","year":"2008","journal-title":"J clin oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:26:25Z","timestamp":1746174385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0305737214000693"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.04.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-induced neuropathy: A comprehensive survey","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}